WHAT WE DO

Abilita Therapeutics is an innovation-driven biotechnology company focused on enabling discovery and development of drugs targeting challenging membrane proteins, including G Protein-Coupled Receptors (GPCRs) and ion channels

Most drugs are small molecules and most drug targets are proteins

60% of approved drugs target membrane proteins

Many of these drugs have limited selectivity, meaning they act on more than one protein and may cause undesirable effects

There is a pressing need for new, effective, and safer drugs to treat diseases like cancer, diabetes, inflammation and neurology

To facilitate the discovery of new drugs, scientists need access to high quality protein targets

There is still a deep technological unmet need in the discovery of therapeutic antibodies targeting membrane proteins

THE CHALLENGE

Drug discovery targeting multi-span membrane proteins is inherently difficult due to the notoriously low stability and high conformational flexibility of these target classes, especially when removed from the cellular environment.

This intrinsic characteristic of membrane proteins has greatly limited the success of protein-based small molecule screening and structure-guided drug discovery, as well as antibody discovery efforts.

Discovery processes have evolved to utilize purified protein as a reagent to enable cutting edge screening and computational methods.

Membrane protein targets have largely been left behind due to difficulties in expression and purification linked to instability. Even more so, discovery of biologics has been hampered by similar difficulties for most classes of multi-span membrane proteins.

OUR SOLUTION: ENABLED MEMBRANE PROTEINS (EMPs™)

ANTIBODY DISCOVERY

STRUCTURE-BASED DRUG DISCOVERY

PROTEIN-BASED SMALL MOLECULE DISCOVERY